SCCM
Log In
Forgot username or password?
New User? Sign Up Free.

Educational Symposia

Learn about clinical breakthroughs and advances that lead to better patient care during these thought-provoking presentations. Each session is presented by leading experts in critical care and offers a thorough analysis of the developments and controversies affecting most intensive care unit environments. These sessions, supported by educational grants, are complimentary for all Congress registrants; no additional registration is needed to attend. Located at the west concourse of the Orange County Convention Center.

View the 49th Critical Care Congress Special Events and Sessions Brochure.
 

Advancing the Diagnosis of Pneumonia and Sepsis: Updates for the Critical Care Specialist
This program is supported by an educational grant from BioFire Diagnostics, LLC.
Moderator: Marin H. Kollef, MD

Monday, February 17, 2020
6:15 a.m. - 7:45 a.m.
Room: W224CDGH, Orange County Convention Center

Session Talks

  • The Syndromic Approach to Diagnosis of Infection
    Amanda Harrington
  • Advances in Rapid Diagnostics and Clinical Implications for Sepsis and Pneumonia
    Debra A. Goff
  • Clinical Considerations for Rapid Molecular Diagnostic Testing
    Marin H. Kollef
  • Bridging the Gap Between Diagnostic and Antimicrobial Stewardship
    Amanda Harrington
​Learning Objectives
  • Review available technologies for the rapid diagnosis of sepsis and pneumonia
  • Apply rapid diagnostic test findings to inform a patient management strategy
  • Develop methods to increase collaboration with the multiprofessional care team to improve timely diagnoses

Maintaining Renal Function in Patients With Cirrhosis: New Guidelines and Evidence in Identification and Management of Hepatorenal Syndrome and Acute Kidney Injury
This program is supported by an educational grant from Mallinckrodt Pharmaceuticals
Moderator: Constantine J. Karvellas, MD, MS, FRCPC, FCCM

Monday, February 17, 2020
12:15 p.m. - 1:30 p.m.
Room: W224ABEF, Orange County Convention Center

Session Talks

  • Hepatorenal Syndrome and Acute Kidney Injury: Current Knowledge and Unmet Needs
    Constantine J. Karvellas
  • New Guidelines for Hepatorenal Syndrome and Acute Kidney Injury: Early Identification and Correct Diagnosis
    Jody C. Olson
  • Evidence-Based Best Practices: Pharmacologic Options for Maintaining Renal Function in Hepatorenal Syndrome and Acute Kidney Injury
    William Peppard
  • Applying Evidence-Based Strategies to the Management of Hepatorenal Syndrome and Acute Kidney Injury in the Critical Care Setting
    Constantine J. Karvellas
Learning Objectives
  • Describe current guidelines and position statements for establishing diagnosis of hepatorenal syndrome (HRS) and acute kidney injury (AKI) compared with other AKI etiologies
  • Apply proactive evidence-based pharmacotherapy to patients who both meet criteria for HRS/AKI and show rapid serum creatinine elevation
  • Discuss current evidence in maintaining renal function and improving survival for different pharmacologic, interventional, and surgical treatments in the management of HRS/AKI

Making the Most of the Clinical Toolbox: Improving Outcomes in HABP and VABP
This program is supported by an educational grant from Merck & Co., Inc.
Moderator: Marin H. Kollef, MD

Monday, February 17, 2020
12:15 p.m. - 1:30 p.m.
Room: W224CDGH, Orange County Convention Center

Session Talks

  • HABP and VABP: Epidemiology, Microbiology, and Clinical Consequences
    Marin H. Kollef
  • Pathogen‐Directed Therapies for MDR Infections in HABP and VABP
    Debra A. Goff
  • New and Emerging Therapies: A Closer Look at the Data
    Richard G. Wunderink
  • Individualizing Therapy to Support Antibiotic Stewardship and Improve Outcomes
    Marin H. Kollef, Debra A. Goff, Richard G. Wunderink
Learning Objectives
  • Explain the evolving epidemiology and etiology of hospital‐acquired bacterial pneumonia (HABP) and ventilator‐associated bacterial pneumonia (VABP)
  • Discuss key safety and efficacy data for newer agents being used for the treatment of HABP and VABP
  • Develop tailored treatment strategies for HABP and/or VABP that support the principles of antibiotic stewardship
  • Coordinate with members of the multiprofessional care team to improve timely diagnoses

Anticoagulation Reversal for Life-Threatening Bleeding: A Case-Based Presentation for the Critical Care Team
This program is supported by an educational grant from Portola Pharmaceuticals.
Moderator: Gregory Piazza, MD

Tuesday, February 18, 2020
6:15 a.m. - 7:45 a.m.
Room: W414, Orange County Convention Center

Session Talks

  • Exploring the Clinical Implications of Bleeding: Appreciating the Burden and Risk Associated with Life-Threatening or Uncontrolled Bleeding
    Jorge Antonio Gutierrez
  • The Emergence of Novel Anticoagulation Reversal Agents: An In-Depth Analysis for the Critical Care Team
    Gregory Piazza
  • Ensuring Appropriate Use of Anticoagulation Reversal Agents: The Experts Weigh In
    John Fanikos
Learning Objectives
  • Appraise the risk of bleeding with DOAC therapy, describe the risk factors associated with bleeding, and examine strategies to mitigate these risks in order to improve patient and healthcare system outcomes
  • Differentiate between available and emerging novel, specific anticoagulation reversal agents; assessing their differences and similarities in mechanism of action; and review the latest clinical trial data and practical administration considerations
  • Evaluate the role of the critical care team in developing a protocol for implementation of novel anticoagulation reversal agents and design treatment strategies for patients with bleeding complications